Marco is a biochemist with a strong expertise in Chemical Biology & Drug Development. In his PhD thesis he developed novel methods for fragment-based drug discovery. It was honored by the German Chemical Society with the Klaus Grohe Prize of Medicinal Chemistry. Afterwards he joined the University Chemical Laboratory Cambridge UK, working for the Bill & Melinda Gates Foundation on novel anti-tuberculosis drugs. During his stay at the University of Cambridge Marco was awarded with a prestigious Marie Curie Fellowship of the European Commission for the development of a novel drug class targeting RNA interference. After returning to Germany he co-founded biotx.ai, a company that develops novel statistical tools for efficacy prediction of drug candidates from population data. biotx.ai has received multiple awards for its machine learning technology specifically designed for the analysis of biomedical data.
Marco provides almost a decade of experience in the biotech ecosystem. He is the author of the textbook “Chemical Biology & Drug Discovery”.